Back
 IJCM  Vol.11 No.8 , August 2020
COVID-19: Lymphocyte Subpopulations Monitoring in Critically Ill Patients
Abstract: Background: The alteration of lymphocyte subpopulations can help to predict the severity and the prognosis of severe Coronavirus disease 2019 (COVID-19). Our goal was to describe the kinetics of lymphocyte subsets, and their impact on the severity and mortality in critically ill COVID-19 patients. Methods: We collected demographic data, comorbidities, clinical signs on admission, laboratory findings on admission then a follow-up during hospitalization. Lymphocyte subsets including CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells were counted by flow cytometer. Results: On admission, we observed lymphopenia in 57% of cases, decreased CD3+ T cells in 76% of cases, decreased CD4+ T cells in 81% of cases, decreased CD8+ T cells in 62% of cases, decreased B cells in 52% of cases, and decreased natural killer (NK) cells in 33% of cases. After treatment, decreased CD3+ T cells, decreased CD4+ T cells, decreased CD8+ T cells, and decreased natural killer cells were predictor factors of mortality, in the univariable analysis. Conclusion: CD3+ T cells, CD4+ T cells, CD8+ T cells, and natural killer cells were predictor factors of severity, ICU mortality, and also a useful tool for predicting disease progression.
Cite this paper: Ziadi, A. , Hachimi, A. , Hazime, R. , Brahim, I. , Admou, B. , Douirek, F. , El Adib, A. , Younous, S. and Samkaoui, A. (2020) COVID-19: Lymphocyte Subpopulations Monitoring in Critically Ill Patients. International Journal of Clinical Medicine, 11, 465-473. doi: 10.4236/ijcm.2020.118039.
References

[1]   World Health Organization (2020) Coronavirus Disease (COVID-19) [Internet].
https://www.who.int/docs/default-source/coronaviruse/situation-
reports/20200608-covid-19-sitrep-140.pdf?sfvrsn=2f310900_2


[2]   Driggin, E., Madhavan, M.V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., et al. (2020) Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems during the COVID-19 Pandemic. Journal of the American College of Cardiology, 75, 2352-2371.
https://doi.org/10.1016/j.jacc.2020.03.031

[3]   Bangash, M.N., Patel, J. and Parekh, D. (2020) COVID-19 and the Liver: Little Cause for Concern. The Lancet Gastroenterology and Hepatology, 5, 529-530.
https://doi.org/10.1016/S2468-1253(20)30084-4

[4]   Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. (2020) COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. The Lancet, 395, 1033-1034.
https://doi.org/10.1016/S0140-6736(20)30628-0

[5]   Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5

[6]   Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.
https://doi.org/10.1001/jama.2020.1585

[7]   Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., et al. (2020) Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180, e200994.
https://doi.org/10.1001/jamainternmed.2020.0994

[8]   Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., et al. (2020) High Expression of ACE2 Receptor of 2019-nCoV on the Epithelial Cells of Oral Mucosa. International Journal of Oral Science, 12, Article No. 8.
https://doi.org/10.1038/s41368-020-0074-x

[9]   Zhang, H., Penninger, J.M., Li, Y., Zhong, N. and Slutsky, A.S. (2020) Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target. Intensive Care Medicine, 46, 586-590.
https://doi.org/10.1007/s00134-020-05985-9

[10]   Wan, Y., Shang, J., Graham, R., Baric, R.S. and Li, F. (2020) Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of Virology, 94, e00127-20.
https://doi.org/10.1128/JVI.00127-20

[11]   Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., et al. (2007) Inhibitory Effect of Tumor Cell-Derived Lactic Acid on Human T Cells. Blood, 109, 3812-3819.
https://doi.org/10.1182/blood-2006-07-035972

[12]   Liao, Y.C., Liang, W.G., Chen, F.W., Hsu, J.H., Yang, J.J. and Chang, M.S. (2002) IL-19 Induces Production of IL-6 and TNF-α and Results in Cell Apoptosis through TNF-α. The Journal of Immunology, 169, 4288-4297.
https://doi.org/10.4049/jimmunol.169.8.4288

[13]   Fan, B.E., Chong, V.C.L., Chan, S.S.W., Lim, G.H., Lim, K.G.E., Tan, G.B., et al. (2020) Hematologic Parameters in Patients with COVID-19 Infection. American Journal of Hematology, 95, E131-E134.
https://doi.org/10.1002/ajh.25774

[14]   Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F.X., Chong, M., et al. (2020) Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State. JAMA Journal of the American Medical Association, 323, 1612-1614.
https://doi.org/10.1001/jama.2020.4326

[15]   Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720.
https://doi.org/10.1056/NEJMoa2002032

[16]   D’Alessandro, M., Bennett, D., Montagnani, F., Cameli, P., Perrone, A., Bergantini, L., et al. (2020) Peripheral Lymphocyte Subset Monitoring in COVID19 Patients: A Prospective Italian Real-Life Case Series. Minerva Medica.

[17]   Liu, Z., Long, W., Tu, M., Chen, S., Huang, Y., Wang, S., et al. (2020) Lymphocyte Subset (CD4+, CD8+) Counts Reflect the Severity of Infection and Predict the Clinical Outcomes in Patients with COVID-19. Journal of Infection.
https://doi.org/10.1016/j.jinf.2020.03.054

[18]   Charlson, M.E., Pompei, P., Ales, K.L. and MacKenzie, C.R. (1987) A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation. Journal of Chronic Diseases, 40, 373-383.
https://doi.org/10.1016/0021-9681(87)90171-8

[19]   Moreno, R., Vincent, J.L., Matos, R., Mendonça, A., Cantraine, F., Thijs, L., et al. (1999) The Use of Maximum SOFA Score to Quantify Organ Dysfunction/Failure in Intensive Care. Results of a Prospective, Multicentre Study. Intensive Care Medicine, 25, 686-696.
https://doi.org/10.1007/s001340050931

[20]   Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., et al. (2020) Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. The Journal of Infectious Diseases, 221, 1762-1769.
https://doi.org/10.1093/infdis/jiaa150

[21]   Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A. and Ng, L.F.P. (2020) The Trinity of COVID-19: Immunity, Inflammation and Intervention. Nature Reviews Immunology, 20, 363-374.
https://doi.org/10.1038/s41577-020-0311-8

[22]   Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., et al. (2020) Relationships among Lymphocyte Subsets, Cytokines, and the Pulmonary Inflammation Index in Coronavirus (COVID-19) Infected Patients. British Journal of Haematology, 189, 428-437.
https://doi.org/10.1111/bjh.16659

[23]   Huang, I. and Pranata, R. (2020) Lymphopenia in Severe Coronavirus Disease-2019 (COVID-19): Systematic Review and Meta-Analysis. Journal of Intensive Care, 8, 36.
https://doi.org/10.1186/s40560-020-00453-4

 
 
Top